121 lines
41 KiB
Text
121 lines
41 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK581694">
|
|
<meta name="ncbi_domain" content="livertox">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK581694/?report=reader">
|
|
<meta name="ncbi_pagename" content="Tirzepatide - LiverTox - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Tirzepatide - LiverTox - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/livertox/Tipranavir/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/livertox/TisotumabVedotin/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/livertox/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]">
|
|
<meta name="citation_title" content="Tirzepatide">
|
|
<meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="citation_date" content="2022/06/20">
|
|
<meta name="citation_pmid" content="35780672">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK581694/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Tirzepatide">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases">
|
|
<meta name="DC.Date" content="2022/06/20">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK581694/">
|
|
<meta name="description" content="Tirzepatide is an agonist of the receptors of two insulin sensitizing polypeptides, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide 1), that is used for type 2 diabetes. Tirzepatide has not been linked to elevations in serum aminotransferase levels during therapy or to episodes of clinically apparent liver injury.">
|
|
<meta name="og:title" content="Tirzepatide">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Tirzepatide is an agonist of the receptors of two insulin sensitizing polypeptides, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide 1), that is used for type 2 diabetes. Tirzepatide has not been linked to elevations in serum aminotransferase levels during therapy or to episodes of clinically apparent liver injury.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK581694/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/livertox/Tirzepatide/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK581694/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8BDB057D7F3B010000000000D200A6.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK581694/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/livertox/Tipranavir/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Tirzepatide</div><div class="j">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</div></div><div class="tail"><a href="/books/n/livertox/TisotumabVedotin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK581694/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK581694/&text=Tirzepatide"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/livertox/?report=reader">Title Information</a><a href="/books/n/livertox/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK581694/?report=classic">Switch to classic view</a><a href="/books/NBK581694/pdf/Bookshelf_NBK581694.pdf">PDF (95K)</a><a href="/books/NBK581694/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK581694%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8BDB057D7F3B010000000000D200A6.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK581694_"><span class="title" itemprop="name">Tirzepatide</span></h1><p class="fm-aai"><a href="#_NBK581694_pubdet_">Publication Details</a></p></div></div><div class="body-content whole_rhythm" itemprop="text"><div id="Tirzepatide.OVERVIEW"><h2 id="_Tirzepatide_OVERVIEW_">OVERVIEW</h2><div id="Tirzepatide.Introduction"><h3>Introduction</h3><p>Tirzepatide is an agonist of the receptors of two insulin sensitizing polypeptides, GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide 1), that is used for type 2 diabetes. Tirzepatide has not been linked to elevations in serum aminotransferase levels during therapy or to episodes of clinically apparent liver injury.</p></div><div id="Tirzepatide.Background"><h3>Background</h3><p>Tirzepatide (tir zep’ a tide) is a 39 amino acid modified peptide similar in structure to the glucose-dependent insulinotropic polypeptide (GIP) that acts as an agonist to both the GIP receptor and the glucagon-like peptide 1 (GLP-1) receptor. Tirzepatide therapy increases insulin secretion, decreases glucagon secretion and delays gastric emptying. The result is a decrease in both fasting and postprandial glucose concentrations and an increase in insulin sensitivity. Tirzepatide also results in a decrease in food intake and reduced body weight. In multiple, preregistration clinical trials, tirzepatide therapy improved glycemic control and lowered HgA1c levels in patients with type 2 diabetes. It also resulted in weight loss of 7 to 11 kilograms after 40 to 52 weeks of treatment and to 16 to 24 kilograms after 72 weeks. Tirzepatide was approved for use as an adjunct to diet and exercise in type 2 diabetes in 2022. It is under active evaluation as a weight loss agent for individuals with overweight or obesity but without diabetes and as a potential therapy for nonalcoholic steatohepatitis. Tirzepatide is available as a solution in single use vials of 2.5, 5, 7.5, 10, 12.5 and 15 mg (in 0.5 mL) under the brand name Mounjaro. The recommended starting dosage for type 2 diabetes is 2.5 mg subcutaneously once weekly, with gradual dose escalation in increments of 2.5 mg every 4 weeks to a maximum of 15 mg weekly. Common adverse events include injection site reactions and nonspecific gastrointestinal complaints of nausea, vomiting, diarrhea, constipation, decreased appetite, dyspepsia, and abdominal discomfort. Less common but potentially severe adverse events include hypersensitivity reactions, pancreatitis, gallstones and cholecystitis, hypoglycemia (when used with insulin or insulin secretagogues) and worsening of preexisting severe renal and gastrointestinal diseases.</p></div><div id="Tirzepatide.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>In preregistration clinical trials, serum aminotransferase elevations of greater than 3 times the upper limit of normal (ULN) arose in less than 1% of patients during therapy with tirzepatide and similar rates occurred in placebo recipients and in comparator arm groups. In studies of more than 5,000 patients, there were no reports of severe liver test abnormalities or clinically apparent liver injury attributable to tirzepatide. However, tirzepatide has been associated with a slightly higher rate of acute gallbladder disease (cholelithiasis, biliary cholic and cholecystectomy) reported in 0.6% of treated patients vs none of placebo-treated patients. Gallbladder conditions are mentioned in the warning section of the product label for tirzepatide.</p><p>Likelihood score: E (unlikely cause of clinically apparent liver injury).</p></div><div id="Tirzepatide.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which tirzepatide might cause liver injury is unknown. It is a modified polypeptide and is metabolized to individual amino acids in multiple tissues and cell types including the liver. Because it causes weight loss, it can be accompanied by improvements in serum aminotransferase levels in patients with preexisting nonalcoholic fatty liver. The increased risk of acute gallbladder disease such as cholecystitis is probably related to the rapid weight loss that occurs with treatment.</p></div><div id="Tirzepatide.Outcome_and_Management"><h3>Outcome and Management</h3><p>Tirzepatide has not been shown to cause liver injury.</p><p>Drug Class: <a href="/books/n/livertox/Antidiabetic/?report=reader">Antidiabetic Agents</a></p><p>Other Related Drugs: <a href="/books/n/livertox/IncretinBasedDrugs/?report=reader">Incretin-Based Drugs</a>, <a href="/books/n/livertox/GLP-1Analogues/?report=reader">Glucagon-Like Peptide-1 (GLP-1) Analogues</a>, <a href="/books/n/livertox/Liraglutide/?report=reader">Liraglutide</a>, <a href="/books/n/livertox/Semaglutide/?report=reader">Semaglutide</a></p></div></div><div id="Tirzepatide.PRODUCT_INFORMATION"><h2 id="_Tirzepatide_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
|
<b>REPRESENTATIVE TRADE NAMES</b>
|
|
</p><p>Tirzepatide – Mounjaro®</p><p>
|
|
<b>DRUG CLASS</b>
|
|
</p><p>Antidiabetic Agents</p><p>
|
|
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Tirzepatide" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
|
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Tirzepatide.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Tirzepatide_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figTirzepatideTc"><a href="/books/NBK581694/table/Tirzepatide.Tc/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobTirzepatideTc"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="Tirzepatide.Tc"><a href="/books/NBK581694/table/Tirzepatide.Tc/?report=objectonly" target="object" rid-ob="figobTirzepatideTc">Table</a></h4></div></div></div><div id="Tirzepatide.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Tirzepatide_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 June 2022</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Tirzepatide.REF1">Abbreviations used: GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c.</div></li><li><div class="bk_ref" id="Tirzepatide.REF.zimmerman.1999">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.<div><i>(Textbook of hepatotoxicity published in 1999; before the availability of tirzepatide).</i></div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.de_marzio.2011">De Marzio DH, Navarro VJ. Antidiabetic drugs. Hepatotoxicity of cardiovascular and antidiabetic drugs. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2011, pp. 528-30.<div><i>(Review of hepatotoxicity of antidiabetic drugs; mentions that there have been no published reports of hepatotoxicity of the GLP-1 analogues, tirzepatide is not discussed).</i></div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.powers.2018">Powers AC, D'Alessio D. Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 863-86.<div><i>(Textbook of pharmacology and therapeutics; discusses glucagon-like peptide-1 and the incretin pathway and agents that act on this pathway, but does not discuss tirzepatide).</i></div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.fda">FDA. <a href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215866Orig1s000MedR.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://www<wbr style="display:inline-block"></wbr>​.accessdata<wbr style="display:inline-block"></wbr>​.fda.gov/drugsatfda_docs<wbr style="display:inline-block"></wbr>​/nda/2022/215866Orig1s000MedR.pdf</a>.<div><i>(FDA website with multidisciplinary review of safety and efficacy of tirzepatide mentions that marked aminotransferase elevations were uncommon and there were no severe hepatic adverse events in preregistration controlled trials, but that gallbladder disease arose in some treated patients [0.6%] but not in controls [none]).</i></div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.frias.2018.2180">Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. <span><span class="ref-journal">Lancet. </span>2018;<span class="ref-vol">392</span>(10160):2180–2193.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/30293770" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30293770</span></a>]<div>
|
|
<i>(Among 316 patients with type 2 diabetes treated with once weekly tirzepatide [1,5,10 and 1 5 mg], dulaglutide [1.5 mg] or placebo for 26 weeks, decreases in HbA1c levels and body weight occurred in a dose-dependent pattern with tirzepatide, and adverse events included gastrointestinal complaints and injection site reactions while cholecystitis occurred in 1 and pancreatitis in 2 of the 211 tirzepatide treated patients).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.hartman.2020.1352">Hartman ML, Sanyal AJ, Loomba R, Wilson JM, Nikooienejad A, Bray R, Karanikas CA, et al. Effects of novel dual GIP and GLP-1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. <span><span class="ref-journal">Diabetes Care. </span>2020;<span class="ref-vol">43</span>:1352–1355.</span> [<a href="/pmc/articles/PMC7245348/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC7245348</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32291277" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 32291277</span></a>]<div>
|
|
<i>(Reanalysis of a controlled trial in 316 patients with type 2 diabetes [Frias 2018], found a decrease in mean ALT levels and increase in adiponectin levels in patients treated with higher doses of tirzepatide [5, 10 and 15 mg], but not with the lowest dose [1 mg] or with dulaglutide or placebo for 26 weeks).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.yanovski.2021.129">Yanovski SZ, Yanovski JA. Progress in pharmacotherapy for obesity. <span><span class="ref-journal">JAMA. </span>2021;<span class="ref-vol">326</span>:129–130.</span> [<a href="/pmc/articles/PMC8277731/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8277731</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34160571" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34160571</span></a>]<div>
|
|
<i>(Brief review of the currently approved drugs for weight loss including the promising two new GLP-1 agonists, liraglutide and semaglutide, and tirzepatide which is in phase III trials in patients with obesity without diabetes).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.fr_as.2021.503">Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, et al. SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. <span><span class="ref-journal">N Engl J Med. </span>2021;<span class="ref-vol">385</span>:503–515.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34170647" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34170647</span></a>]<div>
|
|
<i>(Among 1879 patients with diabetes treated with tirzepatide [5, 10 or 15 mg] or semaglutide [1 mg] once weekly for 40 weeks, tirzepatide resulted in greater improvement in HbA1c levels and greater decrease in body weight [-7.6 to -11.2 kg vs -5.7 kg], while adverse event rates were similar, except for cholecystitis which arose in 12 of 1409 patients on tirzepatide vs no patients on semaglutide [0.9% vs 0%]; no mention of ALT elevations, mean levels decreased by 22% to 30%).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.rosenstock.2021.143">Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. <span><span class="ref-journal">Lancet. </span>2021;<span class="ref-vol">398</span>(10295):143–155.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34186022" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34186022</span></a>]<div>
|
|
<i>(Among 478 diabetic patients with in adequate control treated with tirzepatide [5, 10, or 15 mg] or placebo once weekly for 40 weeks, HbA1c and fasting serum glucose levels improved and weight decreased by 7 to 9.5 kg while adverse events include nausea, diarrhea, constipation, dyspepsia, decreased appetite, and injection site reactions [2%-3%], while no patient developed pancreatitis and only 1 cholecystitis; no mention of ALT elevation or hepatoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.ludvik.2021.583">Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. <span><span class="ref-journal">Lancet. </span>2021;<span class="ref-vol">398</span>(10300):583–598.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34370970" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34370970</span></a>]<div>
|
|
<i>(Among 1444 patients with type 2 diabetes on metformin treated with once weekly tirzepatide [5, 10 or 15 mg] or daily insulin, tirzepatide was associated with greater decreases in HbA1c levels and body weight [-7.5 to -12.9 kg vs +2.3 kg] while gallbladder events were recorded in 4 [0.4%] on tirzepatide, but none on insulin; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.del_prato.2021.1811">Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, et al. SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. <span><span class="ref-journal">Lancet. </span>2021;<span class="ref-vol">398</span>(10313):1811–1824.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/34672967" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 34672967</span></a>]<div>
|
|
<i>(Among 2002 patients with poorly controlled type 2 diabetes treated with weekly injections of tirzepatide [5, 10 or 15 mg] or daily insulin glargine [titrated doses], HbA1c and fasting glucose levels improved more with tirzepatide as did weight loss [-7.1 to -13.5 kg vs +2 kg] while adverse event rates were similar except for diarrhea, nausea, vomiting, dyspepsia, constipation and decreased appetite, which were more common with tirzepatide but decreased over time; pancreatitis and cholecystitis occurred in less than 1% in all groups; no mention of ALT levels or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.dahl.2022.534">Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, Rodríguez Á. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 Randomized Clinical Trial. <span><span class="ref-journal">JAMA. </span>2022;<span class="ref-vol">327</span>(6):534–545.</span> [<a href="/pmc/articles/PMC8826179/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC8826179</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35133415" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35133415</span></a>]<div>
|
|
<i>(Among 475 patients with type 2 diabetes and inadequate glycemic control despite insulin therapy treated with tirzepatide [5, 10 or 15 mg] or placebo weekly for 40 weeks, HbA1c and fasting glucose levels decreased more with tirzepatide as did body weight while adverse events more frequent with tirzepatide included nausea, vomiting, diarrhea, constipation, dyspepsia, decreased appetite; no patient developed pancreatitis and only one cholelithiasis; no mention of ALT elevations or hepatotoxicity).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.sun.2022.e2116506119">Sun B, Willard FS, Feng D, Alsina-Fernandez J, Chen Q, Vieth M, Ho JD, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. <span><span class="ref-journal">Proc Natl Acad Sci U S A. </span>2022;<span class="ref-vol">119</span>:e2116506119. </span> [<a href="/pmc/articles/PMC9060465/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC9060465</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35333651" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35333651</span></a>]<div>
|
|
<i>(Cryogenic electron microscopy determination of structure and binding of tirzepatide to the GIP- and GLP-1 receptors).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF15">Drugs and devices for weight management. <span><span class="ref-journal">Med Lett Drugs Ther. </span>2022;<span class="ref-vol">64</span>:81–88.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/35650672" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35650672</span></a>]<div>
|
|
<i>(Concise review of weight loss agents in current use in the US mentions that tirzepatide [an investigational agent] in doses of 5, 10 and 15 mg once weekly for 72 weeks resulted in weight loss of -16 to -24 kg [compared to +2 kg in placebo controls] in overweight and obese adults without diabetes).</i>
|
|
</div></div></li><li><div class="bk_ref" id="Tirzepatide.REF.jastreboff.2022">Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, et al. Tirzepatide once weekly for the treatment of obesity. <span><span class="ref-journal">N Engl J Med. </span>2022 Jun 4;</span> Epub ahead of print. [<a href="https://pubmed.ncbi.nlm.nih.gov/35658024" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 35658024</span></a>]<div>
|
|
<i>(Among 2539 obese or overweight non-diabetic adults treated with tirzepatide [5, 10 or 15 mg] or placebo once weekly for 72 weeks, weight loss was greater with tirzepatide [-16 to -24 kg] than placebo [-3 kg] and adverse events attributed to tirzepatide included nausea, vomiting, diarrhea, constipation and injection site reactions; pancreatitis occurred in 0.2% vs 0.2%, gallbladder disease in 1.2% vs 0.8%, and mean ALT levels decreased by 26% to 30% vs 13%; no mention of ALT elevations).</i>
|
|
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK581694_pubdet_">Publication Details</h2><h3>Publication History</h3><p class="small">Last Update: <span itemprop="dateModified">June 20, 2022</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Tirzepatide. [Updated 2022 Jun 20].<span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/livertox/Tipranavir/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/livertox/TisotumabVedotin/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobTirzepatideTc"><div id="Tirzepatide.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK581694/table/Tirzepatide.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Tirzepatide.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_Tirzepatide.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_Tirzepatide.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_Tirzepatide.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_Tirzepatide.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_Tirzepatide.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tirzepatide</td><td headers="hd_h_Tirzepatide.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/381128222" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">2023788-19-2</a>
|
|
</td><td headers="hd_h_Tirzepatide.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Protein</td><td headers="hd_h_Tirzepatide.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Polypeptide</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|